Short Interest in Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Decreases By 78.8%

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 1,501 shares, a drop of 78.8% from the June 30th total of 7,095 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 118,747 shares, the days-to-cover ratio is presently 0.0 days.

Sigyn Therapeutics Stock Performance

OTCMKTS:SIGY opened at $0.03 on Friday. The firm has a market cap of $75,946.00, a P/E ratio of -0.01 and a beta of -0.08. The stock has a 50 day moving average of $0.04 and a two-hundred day moving average of $0.23. Sigyn Therapeutics has a 12 month low of $0.01 and a 12 month high of $5.00.

Sigyn Therapeutics (OTCMKTS:SIGY) last issued its quarterly earnings results on Thursday, July 16th. The company reported ($0.42) earnings per share (EPS) for the quarter.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.